Join Olema Oncology as a Principal Talent Acquisition Partner to lead recruiting efforts for R&D and G&A functions in a growing biopharmaceutical company.
Posted by employer 1 day ago
First seen on Joblaze 7 hours ago
Last verified on the company career page 7 hours ago
What you'll build
Must have
Nice to have
Requirements
Not disclosed in this posting: work arrangement, visa sponsorship.
Joblaze summary
The Principal Talent Acquisition Partner at Olema Oncology is responsible for leading full-cycle recruiting efforts across various R&D and G&A functions, focusing on building a skilled workforce to support the company's oncology initiatives. This role requires expertise in biotechnology recruiting, particularly in clinical development and operations, along with the ability to engage passive candidates and manage multiple searches simultaneously. Ideal candidates will have extensive experience in talent acquisition within the biotech or pharmaceutical sectors, particularly in oncology. Olema's collaborative environment emphasizes adaptability and a commitment to advancing cancer treatment.
Joblaze insights
Quick facts
From the original posting
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.
Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year.
Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day.
If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.
The Principal Talent Acquisition Partner, R&D and G&A will play a critical role in building the scientific, clinical, technical, and corporate capabilities required to advance Olema’s portfolio and support the company’s continued growth. Reporting to the Senior Director and Head of Talent Acquisition, this individual will serve as the lead recruiting partner for R&D and G&A and personally drive full-cycle hiring across Clinical Development and Operations, Regulatory Affairs, Research, Quality, CMC and Technical Operations, Biometrics, Pharmacovigilance, Finance, Legal, People, IT, Communications, Business Development, and related functions.
This is a highly visible, hands-on individual contributor role for an accomplished recruiter who understands the specialized talent required to discover, develop, and advance oncology therapies while also bringing the versatility to recruit across corporate functions. The successful candidate will combine deep biotechnology recruiting expertise with strong sourcing instincts, sound judgment, and the ability to translate complex scientific, functional, and business needs into effective recruiting strategies.
This individual will proactively identify and engage exceptional passive talent, build pipelines for current and anticipated needs, and convert highly qualified prospects into successful hires. They must be comfortable simultaneously advancing multiple searches across diverse functions and levels while maintaining urgency, quality, and a high-touch candidate experience.
Operating within Olema’s broader talent acquisition strategy, this individual will lead R&D and G&A recruiting execution and serve as a trusted talent expert across these functions. This is a senior individual contributor position.
Key Responsibilities
Recruiting and Partnership
Pipeline Development and Talent Intelligence
Candidate Assessment, Closing, and Negotiation
Recruiting Operations and Performance
Qualifications
The base pay range for this position is expected to be $190,000 - $225,000 annually, however the base pay offered may vary depending on location, market, job related knowledge, skills and capabilities, and experience. The total compensation package for this position also includes equity, bonus, and benefits.
#LI-AD1
Important Information >>>
Standard company text repeated across Olema Oncology's postings is omitted here.